Xinqiao Hospital of Chongqing
123
18
20
34
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
4.9%
6 terminated/withdrawn out of 123 trials
85.0%
-1.6% vs industry average
20%
25 trials in Phase 3/4
3%
1 of 34 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (123)
Multimodal Risk Factor Graph Mapping, Metabolic Subtyping, and Digital Intelligent Chronic Disease Management for Prediabetes: An Integrated Cohort and Case-Control Clinical Study
Role: collaborator
A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Role: lead
Intravenous Tirofiban Versus Thrombolysis Before Mechanical Thrombectomy in Stroke
Role: lead
The Effect of Perioperative Nutritional Assessment and Nutritional Support on Clinical Outcomes
Role: collaborator
Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke
Role: lead
Tirofiban Combined With Aspirin in Moderate Ischemic Stroke
Role: lead
Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)
Role: lead
HBV Reactivation Prediction Model in Allo-HSCT
Role: collaborator
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Role: collaborator
Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
Role: collaborator
3-Dimensional Simulation Guided Transcatheter Aortic Valve Replacement in Aortic Regurgitation(DIGITAL)
Role: collaborator
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation
Role: collaborator
Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases
Role: lead
HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer
Role: lead
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
Role: lead
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC
Role: lead
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Role: lead
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
Role: lead
EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma
Role: lead
Application of mRNA Immunotherapy Technology in EB Virus Related Diseases
Role: lead